Undisclosed ApoA1-Anti CD99 antibody fusion protein
/ NanoValent Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Enhanced therapeutic efficacy of ApoA1-Anti CD99 antibody fusion protein for treatment of Ewing sarcoma
(AACR 2026)
- "Abstract is embargoed at this time."
Clinical • Late-breaking abstract • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor • APOA1 • CD99
1 to 1
Of
1
Go to page
1